Ivosidenib (Tibsovo)

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search

General information

Class/mechanism: IDH1 inhibitor. Ivosidenib inhibits the mutant isocitrate dehydrogenase 1 (IDH1) enzyme at lower drug concentrations than wild-type IDH1. Inhibiting mutant IDH1 enzyme prevents formation of the oncometabolite 2-hydroxyglutarate (2HG) in leukemia cells, causes a reduction in IDH1-expressing tumor cells, and increases percentages of mature myeloid cells.[1][2][3]

Diseases for which it is used

Patient drug information

History of changes in FDA indication

Acute myeloid leukemia

Cholangiocarcinoma

Also known as

  • Code name: AG-120
  • Brand name: Tibsovo

References